Neuroscience 2005 Abstract
| Presentation Number: | 881.3 |
|---|---|
| Abstract Title: | Low doses of scopolamine disrupt attention and other non-mnemonic behaviors. |
| Authors: |
Hodges, D. B.*1,2
; Lindner, M. D.1
; Hogan, J. B.1
; Markus, E. J.2
1Pharmaceutical Research Inst., Neuroscience Drug Discovery , Bristol-Myers Squibb, Wallingford, CT 2CT, 5 Research Parkway, 06492-7660, |
| Primary Theme and Topics |
Cognition and Behavior - Animal Cognition and Behavior -- Cognitive learning and memory systems |
| Secondary Theme and Topics | Cognition and Behavior<br />- Animal Cognition and Behavior<br />-- Learning and memory: Pharmacology |
| Session: |
881. Cognitive Learning and Memory Systems: Cognition and Neurotransmitters Poster |
| Presentation Time: | Wednesday, November 16, 2005 10:00 AM-11:00 AM |
| Location: | Washington Convention Center - Hall A-C, Board # JJ5 |
| Keywords: | CHOLINERGIC, MEMORY, RAT, MUSCARINIC |
It is well established that the degeneration of cholinergic systems plays a role in the decline of cognitive functions in Alzheimer’s disease, and cholinergic antagonists are often used to model the cognitive deficits of Alzheimer’s dementia. However cholinergic antagonists such as scopolamine (a nonselective postsynaptic muscarinic receptor antagonist), may produce deficits in non-mnemonic functions. The objective of the present study was to assess the effects of scopolamine on measures of motor function using a simple bar-pressing task (FR5); a test of short-term memory and attention, delayed non-matching to position (DNMTP); a test of working memory, the radial arm maze (RAM); and a spatial mapping task, the Morris water maze (MWM). A single group of Long Evans rats was tested using a within-subjects, Latin square design in each of the four behavioral tests with saline and five doses of scopolamine. In the FR5 test of motor function, 0.03 mg/kg scopolamine produced significant deficits In DNMTP, percent correct choices was reduced by 0.1 mg/kg. In the RAM, working memory was disrupted by 0.3 mg/kg dose, and in the MWM, 0.1 mg/kg dose increased cumulative error and total swim distance. The non-mnemonic effects of scopolamine in the FR5 test of motor function, and movement initiation in DNMTP were more robust than the effects of scopolamine on percent correct choices in DNMTP, number of errors in the RAM and swim distance and cumulative error in the MWM. These results suggest that the non-mnemonic effects of scopolamine may be more substantial than its effects on learning and memory.
Supported by Bristol-Myers Squibb PRI; UConn FRS445142; NIH #R29-A613941-01A1
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2005 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2005. Online.
Copyright © 2005-2026 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
